STEM CELL THERAPEUTIC

US ‘Stem cells regenerative medicine congress’ invites MEDIPOST for the first time as a Korean company

MEDIPOST, achieves ‘150 patent applications and 50 patent registrations’

Core dementia treatment technology patented at 6 European countries, concurrently

‘CARTISTEM’ shows superb results from 3 year long term tracking clinical trials

Lung disease medicine, ‘PNEUMOSTEM’ was designated as ‘Orphan Drug’ in Europe

‘CARTISTEM’ injection to U.S. clinical trial subject completed

U.S. ABC News gave intensified coverage on ‘CARTISTEM’

Participation in Biotec Japan and local publicity activities on CARTISTEM

The only Korean company invited to North American Rare Medicine conference

Administration of lung disease medicine ‘PNEUMOSTEM’ in clinical trial completed

Administration of lung disease medicine ‘PNEUMOSTEM’ started in U.S. clinical trial

Accumulated Dosage of CARTISTEM Exceeds 2,000 Cases